Afrezza Kit
Product Images NDC 47918-904

Product Visual Gallery

This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Afrezza (NDC 47918-904). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mannkind Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3. Mean Insulin Effect And Pharmacokinetic Profiles (Figure 3 Pkpd)

Two line graphs labeled A and B showing pharmacokinetic and pharmacodynamic profiles of AFREZZA inhalation powder at doses of 48, 12, and 4 units. Graph A plots glucose infusion rate (mg/kg/min) over 360 minutes, showing varying GIR peaks for each dose. Graph B plots insulin concentration (µU/mL) over 360 minutes, with the highest insulin level seen at 48 units AFREZZA, decreasing with time and lower doses.*

FDA Label Image

Ifu Know Your Cartridges

Illustration showing AFREZZA inhalation powder packaging and cartridge details. It depicts one foil package containing 2 blister cards, each with 5 strips of 3 cartridges per strip. Three cartridge strengths are shown: 4 units in blue, 8 units in green, and 12 units in yellow, each with corresponding cartridge cups and color markings.*

FDA Label Image

Ifu Open Packages

Packaging label for Afrezza (Insulin Human) inhalation powder by Mannkind Corporation. The label indicates dosing in units per cartridge and shows a strip of blister packs containing cartridges of the powder. Instructions note the single-use nature of each cartridge with visual emphasis on cartridge handling.*

FDA Label Image

Ifu Room Temp Storage

This text panel titled 'In Use: Room Temperature Storage' provides storage instructions for opened foil packages of AFREZZA powder. It explains use timelines for sealed (unopened) blister cards and strips, which must be used within 10 days at room temperature, and opened strips, which must be used within 3 days. A caution advises against returning blister cards or strips to the refrigerator after room temperature storage.*

FDA Label Image

Ifu Store Refrigerated

Drug storage instructions for Afrezza Insulin Human Powder for inhalation are shown. It advises refrigerated storage of unopened foil packages until expiration and unopened blister cards/strips must be used within one month. The image includes a refrigerator graphic and temperature range 36-46°F (2-8°C) for storage.*

FDA Label Image

Figure 1 Mealtime Afrezza Starting Dose Conversion Table (Afrezza 01)

A dosing chart for AFREZZA (insulin human) powder, metered, via respiratory inhalation. It shows the required number and combination of cartridges in 4-unit (blue), 8-unit (green), and 12-unit (yellow) strengths based on the injected mealtime insulin dose, ranging from up to 4 units to 21-24 units.*

FDA Label Image

Figure 2 (Mean Change in FEV)

A line graph comparing the change from baseline in FEV1 (L) over time between AFREZZA and a comparator. The x-axis represents study visits from baseline through month 24, and the y-axis shows change from baseline in FEV1 with values from -0.3 to 0.1 liters. Two lines depict the mean changes, with AFREZZA consistently showing a greater decrease than the comparator across all visits. The graph includes sample sizes (n) for each visit.*

FDA Label Image

Chemical Structure (Afrezza 03)

Chemical structure diagram of Insulin human showing the amino acid sequence and disulfide bonds connecting two peptide chains.*

FDA Label Image

Figure A (Image of Cartridges)

Three individual cartridge unit dose blister packs for AFREZZA insulin human powder, metered for respiratory inhalation by Mannkind Corporation. Each dose is color-coded: blue for 4 units, green for 8 units, and yellow for 12 units of insulin human.*

FDA Label Image

Diagram Of Inhaler (Afrezza 06)

Illustration showing components of the AFREZZA inhaler device used for insulin human powder inhalation. The diagram labels the removable purple mouthpiece cover, white mouthpiece, cartridge, white cartridge cup, purple base, and indicates the top and bottom of the inhaler. An arrow shows the cartridge being inserted into the base assembly.*

FDA Label Image

Cartridge Selection Based On Color (Afrezza 08)

An instructional illustration showing cartridge color coding for AFREZZA inhalation powder. It shows a blue cartridge for a 4-unit dose, a green cartridge for an 8-unit dose, and a yellow cartridge for a 12-unit dose, each with a corresponding inhaler device image.*

FDA Label Image

Figure B (Dosage Chart)

Illustration showing the number of AFREZZA insulin cartridges needed for doses ranging from 4 to 24 units. Color-coded cartridges include blue for 4-unit, green for 8-unit, and yellow for 12-unit doses, with combinations depicted for different total dose amounts.*

FDA Label Image

Example Combination (Afrezza 10)

An instructional illustration demonstrating how to combine cartridges for the AFREZZA insulin inhalation powder. It shows using one green cartridge representing 8 units and one yellow cartridge representing 12 units to total 20 units. The green cartridge is labeled '8 unit' and the yellow '12 unit.'*

FDA Label Image

Image Of Pushing Cartridge Out Of Blister (Afrezza 12)

An instructional illustration showing a close-up of hands handling a small, flat strip of medicine. The strip appears to be a blister or strip of metered powder doses, with fingers pinching and peeling back a portion to access the dose inside.*

FDA Label Image

Cartridges And Inhaler Should Be At Room Temperature (Afrezza 13)

An instructional diagram for AFREZZA insulin inhalation powder advising that cartridges and inhaler should be at room temperature for 10 minutes before use. The image includes icons representing room temperature with a thermometer, inhaler, cartridges, and a clock showing 10 minutes.*

FDA Label Image

Image Of Inhaler In Hand (Afrezza 14)

An instructional illustration showing a person holding the Afrezza inhaler device, with fingers positioned to operate it, demonstrating how to prepare for administration of Afrezza insulin powder by inhalation.*

FDA Label Image

Image Of Inhaler Being Opened (Afrezza 15)

An instructional illustration showing a hand opening the lid of a small, rectangular inhalation device. A red arrow indicates the direction to lift the lid, demonstrating how to prepare the device for use with AFREZZA powdered insulin for inhalation.*

FDA Label Image

Image Of Cartridge Being Placed Into Inhaler (Afrezza 16)

An instructional illustration showing a hand inserting a black cartridge into a purple device, with a red arrow indicating the direction for correct placement. The image highlights the loading step for a device related to AFREZZA insulin human powder for inhalation.*

FDA Label Image

Once Loaded Keep Inhaler Level (Afrezza 17)

An instructional diagram for AFREZZA inhaler use showing how to keep the inhaler level once loaded to prevent loss of drug powder. It includes warnings against turning the inhaler upside down, pointing the mouthpiece down, or shaking/dropping the inhaler, illustrating these incorrect actions with crossed-out images.*

FDA Label Image

Image Of Inhaler Being Closed (Afrezza 18)

Instructional diagram showing how to open the AFREZZA inhaler device by lifting the purple mouthpiece upwards, indicated by a red curved arrow. A hand holds the base of the device while another hand lifts the mouthpiece.*

FDA Label Image

Image Of Mouthpiece Cover Being Removed (Afrezza 19)

An instructional illustration showing how to insert a cartridge into a device. The image depicts a hand holding a purple and white cartridge with an arrow pointing to the right, indicating the cartridge should be inserted into a matching purple device held by the other hand.*

FDA Label Image

Check You Are Ready To Inhale (Afrezza 20)

This image shows a text panel titled 'Check that you are ready to inhale,' listing preparatory steps before inhalation using the AFREZZA inhaler. It advises confirming the purple mouthpiece cover is removed, holding the inhaler level, and reviewing A-B-C steps before starting inhalation.*

FDA Label Image

Image Of Exhaling (Afrezza 21)

An instructional illustration showing a user inhaling from a device, indicated by a hand holding the device near the mouth and an arrow showing airflow being directed into the person's mouth. This diagram likely demonstrates how to use the AFREZZA inhalation powder product properly.*

FDA Label Image

Image Of Inhaler Position In Mouth (Afrezza 22)

Illustration showing a person inhaling from a device, demonstrating the correct way to use the inhaler for AFREZZA (insulin human) powder, metered, by respiratory inhalation. The top image shows correct inhalation posture, while the bottom image indicates an incorrect position, emphasizing proper usage technique.*

FDA Label Image

Image Of Deep Inhale (Afrezza 23)

An instructional illustration showing a person using the AFREZZA inhaler device by placing it at the mouth. The figure highlights airflow around the mouth and shows an arrow indicating inhalation through the device, demonstrating respiratory administration of the insulin powder.*

FDA Label Image

Image Of Mouthpiece Cover Being Replaced (Afrezza 24)

An instructional illustration showing a close-up of a device labeled AFREZZA, an inhalation powder form of insulin human. The image depicts the opening or assembly process of the device, indicating a removable or attachable cap being pulled away from the main body of the inhaler.*

FDA Label Image

Image Of Inhaler Being Opened (Afrezza 25)

An instructional illustration showing a person opening the mouthpiece cover of an AFREZZA inhaler device, which is used for respiratory administration of insulin human powder. The hand lifts the purple mouthpiece cover upward, indicated by a red curved arrow, preparing the device for use.*

FDA Label Image

Image Of Cartridge Being Removed (Afrezza 26)

An instructional illustration showing how to load a metered dose of AFREZZA insulin powder into its inhalation device. The image depicts a hand holding the dose cartridge above the open inhaler mouthpiece, with an arrow indicating the cartridge is to be inserted downward into the device.*

FDA Label Image

Image Of Cartridge Being Thrown Away (Afrezza 27)

An instructional illustration depicting a hand disposing of a small cartridge or dose into a trash receptacle labeled 'TRASH'. The image likely shows proper disposal of a used or empty unit related to the AFREZZA insulin inhalation powder system.*

FDA Label Image

Image Of 3 Cartridges (Afrezza 28)

Packaging image showing three plastic inhaler mouthpiece cartridges for AFREZZA insulin human powder, metered dosage form for respiratory inhalation, labeled by Mannkind Corporation. Each cartridge is gray with a clear dispensing tip, used for delivering metered insulin doses by inhalation.*

FDA Label Image

Do Not Mix Used And New Cartridges (Afrezza 29)

An instructional diagram for AFREZZA inhalation powder cartridges showing how to distinguish new cartridges from used ones. New cartridges have the white cup positioned away from the center, while used cartridges have the white cup moved to the middle. Warning text advises not to mix new and used cartridges.*

FDA Label Image

Before Use Cartridges Should Be At Room Temperature (Afrezza 32)

Instructional diagram advising that before use, cartridges and inhaler should be at room temperature for 10 minutes. The image includes a thermometer indicating room temperature and a clock showing 10 minutes.*

FDA Label Image

Inhaler Storage Instructions (Afrezza 33)

Storage instructions for the Afrezza inhaler powder, showing a side view illustration of the inhaler with the mouthpiece covered by a purple cover. The instructions include keeping the inhaler in a clean, dry place with the mouthpiece cover on, optional refrigeration with room temperature prior to use, not leaving cartridges in the inhaler, and keeping the product out of reach of children.*

FDA Label Image

Replace Inhaler Every 15 Days (Afrezza 34)

An illustration of a calendar page displaying dates, with a circle marking a specific date. The caption below the calendar reads 'EVERY 15 DAYS,' indicating a biweekly schedule.*

FDA Label Image

Powder Residue Is Normal; Do Not Wash Inhaler (Afrezza 35)

Text panel providing usage instructions for the AFREZZA inhaler, specifically addressing powder residue in the mouthpiece after dosing as normal and advising on cleaning the outside of the inhaler with a dry cloth only, emphasizing not to wash the inhaler.*

FDA Label Image

Image Of Caution Symbol (Afrezza 36)

FDA Label Image

Dose Conversion Chart (Afrezza 37)

An instructional diagram illustrating how to switch from AFREZZA inhaled insulin powder to injected mealtime insulin. The chart correlates AFREZZA dose units with the number of cartridges needed (4, 8, or 12 unit cartridges) and shows the equivalent injected mealtime insulin dose in units. Visual aids include a cartridge, syringe, and insulin vial. Instructions guide users to find their AFREZZA dose and determine the correct injected insulin dose accordingly.*

FDA Label Image

Dose Conversion Chart (Afrezza 38)

An instructional diagram showing how to switch from injected mealtime insulin to AFREZZA inhalation powder. It includes a chart matching injected insulin doses (in units) to the number and strength of AFREZZA cartridges needed, color-coded by 4, 8, and 12 unit strengths. The diagram visually connects injected insulin syringes and vials to the AFREZZA inhaler device with arrows.*

FDA Label Image

Primary Panels Ndc 47918 874 90

Packaging label for Afrezza (insulin human) inhalation powder by Mannkind Corporation. The label indicates a carton containing 90 cartridges, each with 4 units per cartridge, along with 2 inhalers. The label emphasizes oral inhalation use only and includes the NDC 47918-874-90. The left side shows the Afrezza brand name and generic name with trademark symbols, while the center-right displays images of an Afrezza cartridge and inhaler device.*

FDA Label Image

Principal Display Panel (90 – 8 Unit Kit Carton)

Packaging label for Afrezza inhalation powder containing insulin human. The label shows the product strength of 8 units per cartridge and indicates the carton contains 90 cartridges plus 2 inhalers. The label includes images of a cartridge and an inhaler device and emphasizes oral inhalation only. The labeler is Mannkind Corporation.*

FDA Label Image

Primary Panels Ndc 47918-880-18 (Primary Panels Ndc 47918 880 18)

AFREZZA inhalation powder packaging label for insulin human showing a titration pack containing 180 cartridges. The pack includes 90 cartridges of 4 units each and 90 cartridges of 8 units each, along with 2 inhalers. The label features the Afrezza brand name, dosage strengths, and manufacturer Mannkind Corporation. The image also includes visuals of the cartridge colors (blue for 4 units, green for 8 units) and one inhaler device.*

FDA Label Image

Principal Display Panel (90 – 12 Unit Kit Carton)

AFREZZA 12 units per cartridge inhalation powder packaging label. The label shows the product name AFREZZA (insulin human) Inhalation Powder, manufactured by Mannkind Corporation. It is for oral inhalation only and the carton contains 90 cartridges with 12 units per cartridge plus 2 inhalers. The label also includes a barcode and storage instructions.*

FDA Label Image

Primary Panels Ndc 47918 898 18

Packaging label for AFREZZA (insulin human) Inhalation Powder by Mannkind Corporation. The label shows a titration pack containing 180 cartridges with strengths of 8 units and 12 units per cartridge. The carton includes 90 cartridges of each strength plus 2 inhalers. The label features images of green 8 unit and yellow 12 unit cartridges alongside a purple inhaler device. It specifies the product is for oral inhalation only.*

FDA Label Image

Primary Panels Ndc 47918-902-18 (Primary Panels Ndc 47918 902 18)

Packaging label for Afrezza (insulin human) Inhalation Powder by Mannkind Corporation. The label indicates a titration pack containing 180 cartridges with strengths of 4 units, 8 units, and 12 units per cartridge. Includes 2 inhalers and is labeled for oral inhalation only. The label features images of inhaler device and color-coded cartridges in blue, green, and orange.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.